In a report released yesterday, Jade Rahmani from KBW maintained a Buy rating on DR Horton (DHI – Research Report), with a price target of $178.00. The company’s shares closed yesterday at $151.26.
Rahmani covers the Real Estate sector, focusing on stocks such as Ladder Capital, Arbor Realty, and NexPoint Real Estate ate Finance. According to TipRanks, Rahmani has an average return of 16.1% and a 76.02% success rate on recommended stocks.
In addition to KBW, DR Horton also received a Buy from Barclays’s Matthew Bouley in a report issued on April 19. However, on the same day, J.P. Morgan maintained a Hold rating on DR Horton (NYSE: DHI).
DHI market cap is currently $48.9B and has a P/E ratio of 10.11.
Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHI in relation to earlier this year. Last month, Barbara K. Allen, a Director at DHI sold 363.00 shares for a total of $53,890.98.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DR Horton (DHI) Company Description:
Founded in 1978, Texas-based D.R. Horton, Inc. is a homebuilding company that is engaged in the construction and sale of single-family homes through its diverse brand portfolio that includes D.R. Horton, Emerald Homes, Express Homes and Freedom Homes.
Read More on DHI:
- D.R. Horton price target lowered to $141 from $142 at RBC Capital
- D.R. Horton price target lowered to $168 from $169 at BTIG
- D.R. Horton price target lowered to $168 from $182 at BofA
- D.R. Horton price target raised to $200 from $192 at UBS
- D.R. Horton price target lowered to $176 from $186 at Barclays
